Role of Cannabinoid Receptors in Psychological Disorder

Ambika Nand Jha (1) , Dhaval M Patel (2)
(1) Indubhai Patel College of Pharmacy and Research Center , India
(2) SAL Institute of Pharmacy , India


Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system. Cannabinoid CB1 and CB2 receptors are G protein-coupled receptors present from the early stages of gestation, which is involved in various physiological processes, including appetite, pain-sensation, mood, and memory. Due to the lipophilic nature of cannabinoids, it was initially thought that these compounds exert several biological effects by disrupting the cell membrane nonspecifically. Recent biochemical and behavioral findings have demonstrated that blockade of CB1 receptors engenders antidepressant-like neurochemical changes (increases in extracellular levels of monoamines in cortical but not subcortical brain regions) and behavioral effects consistent with antidepressant/antistress activity. We aim to define various roles of cannabinoid receptors in modulating signaling pathways and association with several pathophysiological conditions.

Full text article

Generated from XML file


Abizaid, A., Merali, Z., & Anisman, H. (2019). Cannabis: A potential efficacious intervention for PTSD or simply snake oil? Journal of Psychiatry and Neuroscience, 44(2), 75-78. doi:10.1503/jpn.190021
Avila, A., Nguyen, L., & Rigo, J.M. (2013). Glycine receptors and brain development. Frontiers in Cellular Neuroscience, 7, 184. doi:10.3389/fncel.2013.00184
Barden, N. (2004). Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression. Journal of Psychiatry and Neuroscience, 29(3), 185-193.
Berg, K.A. & Clarke, W.P. (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology, 21(10), 962-977. doi:10.1093/ijnp/pyy071
Bergamaschi, M.M., Queiroz, R.H.C., Chagas, M.H.N., de Oliveira, D.C.G., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A.E., Martín-Santos, R., Hallak, J.E.C., Zuardi, A.W., & Crippa, J.A.S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226. doi:10.1038/npp.2011.6
Black, J.B., Premont, R.T., & Daaka, Y. (2016). Feedback Regulation of G Protein-Coupled Receptor Signaling by GRKs and Arrestins. Seminars in Cell and Developmental Biology, 50, 95-104. doi:10.1016/j.semcdb.2015.12.015
Boctor, S.Y., Martinez, J.L., Koek, W., & France, C.P. (2007). The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. European Journal of Pharmacology, 571(1), 39-43. doi:10.1016/j.ejphar.2007.06.004
Bruni, N., Pepa, C.D., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018). Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules, 23(10), 2478. doi:10.3390/molecules23102478
Buchwald, P. (2019). A Receptor Model with Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. Frontiers in Pharmacology, 10, 605. doi:10.3389/fphar.2019.00605
Burggren, A.C., Shirazi, A., Ginder, N., & London, E.D. (2019). Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. American Journal of Drug and Alcohol Abuse, 45(6), 563-579. doi:10.1080/00952990.2019.1634086
Cassano, T., Calcagnini, S., Pace L., De Marco, F., Romano, A., & Gaetani, S. (2017). Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Frontiers in Neuroscience, 11, 30. doi:10.3389/fnins.2017.00030
Castillo, P.E., Younts, T.J., Chávez, A.E., & Hashimotodani, Y. (2012). Endocannabinoid signaling and synaptic function. Neuron, 76(1), 70-81. doi:10.1016/j.neuron.2012.09.020
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P.G., & Lagae, L. (2012). Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia, 53(7), 1131-1139. doi:10.1111/j.1528-1167.2012.03495.x
Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R., & Brotchie, J.M. (2000). Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. The FASEB Journal, 14(10), 1432-1438. doi:10.1096/fj.14.10.1432
Donvito, G., Nass, S.R., Wilkerson, J.L., Curry, Z.A., Schurman, L.D., Kinsey, S.G., & Lichtman, A.H. (2018). The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology, 43, 52-79. doi:10.1038/npp.2017.204
Dhopeshwarkar, A. & Mackie, K. (2014). CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold? Molecular Pharmacology, 86(4), 430-437. doi:10.1124/mol.114.094649
Harvey, R.J., Carta, E., Pearce, B.R., Chung, S.K., Supplisson, S., Rees, M.I., & Harvey, K. (2008). A Critical Role for Glycine Transporters in Hyperexcitability Disorders. Frontiers in Molecular Neuroscience, 1, 1. doi:10.3389/neuro.02.001.2008
Hasler, G. (2010). Pathophysiology of Depression: Do We Have Any Solid Evidence of Interest to Clinicians? World Psychiatry, 9(3), 155-161. doi:10.1002/j.2051-5545.2010.tb00298.x
Herman, J.P., McKlveen, J.M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J., & Myers, B. (2016). Regulation of the hypothalamic-pituitary-adrenocortical stress response. Comprehensive Physiology, 6(2), 603-621. doi:10.1002/cphy.c150015
Hill, M.N., Campolongo, P., Yehuda, R., & Patel, S. (2018). Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology, 43(1), 80-102. doi:10.1038/npp.2017.162
Howlett, A.C. & Abood, M.E. (2017). CB1 & CB2 Receptor Pharmacology. Advances in Pharmacology, 80, 169-206. doi:10.1016/bs.apha.2017.03.007
Ibarra-Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, A., & Callado, L.F. (2018). The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochemical Pharmacology, 157, 97-107. doi:10.1016/j.bcp.2018.07.009
Kano, M. (2014). Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 90(7), 235-250. doi:10.2183/pjab.90.235
Kayser, R.R., Snorrason, I., Haney, M., Lee, F.S., & Simpson, H.B. (2019). The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? Cannabis and Cannabinoid Research, 4(2), 77-87. doi:10.1089/can.2018.0049
Kimura, T., Takaya, M., Usami, N., Watanabe, K., & Yamamoto, I. (2019). ∆9-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB1 receptor. Forensic Toxicology, 37(1), 207-214. doi:10.1007/s11419-018-0457-2
Lac, A. & Luk, J.W. (2018). Testing the Amotivational Syndrome: Marijuana Use Longitudinally Predicts Lower Self-Efficacy Even After Controlling for Demographics, Personality, and Alcohol and Cigarette Use. Prevention Science, 19(2), 117-126. doi:10.1007/s11121-017-0811-3
Lawn, W., Freeman, T.P., Pope, R.A., Joye, A., Harvey, L., Hindocha, C., Mokrysz, C., Moss, A., Wall, M.B., Bloomfield, M.A., Das, R.K., Morgan, C.J., Nutt, D.J., & Curran, V. (2016). Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. Psychopharmacology, 233(19-20), 3537-3552. doi:10.1007/s00213-016-4383-x
Lee, J.L.C., Bertoglio, L.J., Guimarães, F.S., & Stevenson, C.W. (2017). Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety‐related and substance abuse disorders. British Journal of Pharmacology, 174(19), 3242-3256. doi:10.1111/bph.13724
Lépine, J.P. & Briley, M. (2011). The increasing burden of depression. Neuropsychiatric Disease and Treatment, 7(Suppl 1), 3-7. doi:10.2147/NDT.S19617
Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter,J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94. doi:10.1038/tp.2012.15
Licastro, F. & Chiappelli, M. (2003). Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mechanisms of Ageing and Development, 124(4), 539-548. doi:10.1016/S0047-6374(03)00034-4
Lu, H.C. & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516-525. doi:10.1016/j.biopsych.2015.07.028
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C.J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 16(12), 705-718. doi:10.1038/nrn4036
Maroof, N., Ravipati, S., Pardon, M.C., Barrett, D.A., & Kendall, D.A. (2014). Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 42(1), 227-245. doi:10.3233/jad-131961
Mayeux, R. & Stern, Y. (2012). Epidemiology of Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2(8), a006239. doi:10.1101/cshperspect.a006239
Meyer, H.C., Lee, F.S., & Gee, D.G. (2018). The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology, 43, 21-33. doi:10.1038/npp.2017.143
Moreira, F.A., Aguiar, D.C., & Guimarães, F.S. (2007). Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology, 52(3), 958-965. doi:10.1016/j.neuropharm.2006.10.013
Navarrete, F., García-Gutiérrez, M.S., Jurado-Barba, R., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020). Endocannabinoid System Components as Potential Biomarkers in Psychiatry. Frontiers in Psychiatry, 11, 315. doi:10.3389/fpsyt.2020.00315
Papagianni, E.P. & Stevenson, C.W. (2019). Cannabinoid Regulation of Fear and Anxiety: An Update. Current Psychiatry Reports, 21(6), 38. doi:10.1007/s11920-019-1026-z
Patel, D.M., Patel, A.B., Trivedi, R.D., Parmar, V.J., & Bangoriya, U.V. (2019). Evaluation of the Effect of Hydroalcoholic Extracts of Cassia Occidentalis Leaves in Neutrophil Adhesion Test in Rats. Journal of Drug Delivery and Therapeutics, 9(4-S), 1218-1221. doi:10.22270/jddt.v9i4-s.3940
Patel, S., Hill, M.N., Cheer, J.F., Wotjak, C.T., & Holmes, A. (2017). The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and Biobehavioral Reviews, 76(Pt A), 56-66. doi:10.1016/j.neubiorev.2016.12.033
Patel, S. & Hillard, C.J. (2009). Role of Endocannabinoid Signaling in Anxiety and Depression. Current Topics in Behavioral Neurosciences, 1, 1-21. doi:10.1007/978-3-540-88955-7_14
Pizza, V., Agresta, A., D’Acunto, C.W., Festa, M., & Capasso, A. (2011). Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS and Neurological Disorders - Drug Targets, 10(5), 621-634. doi:10.2174/187152711796235014
Poleszak, E., Wośko, S., Sławińska, K., Wyska, E., Szopa, A., Sobczyński, J., Wróbel, A., Doboszewska, U., Wlaź, P., Wlaź, A., Szponar, J., Skałecki, P., & Serefko, A. (2020). Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice. Behavioural Brain Research, 378, 112297. doi:10.1016/j.bbr.2019.112297
Ramírez, B.G., Blázquez, C., del Pulgar, T.G., Guzmán, M., & de Ceballos, M.L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25(8), 1904-1913. doi:10.1523/jneurosci.4540-04.2005
Rubino, T., Guidali, C., Vigano, D., Realini, N., Valenti, M., Massi, P., & Parolaro, D. (2008). CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology, 54(1), 151-160. doi:10.1016/j.neuropharm.2007.06.024
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020). Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry, 20, 24. doi:10.1186/s12888-019-2409-8
Shahbazi, F., Grandi, V., Banerjee, A., & Trant, J.F. (2020). Cannabinoids and Cannabinoid Receptors: The Story so Far. iScience, 23(7), 101301. doi:10.1016/j.isci.2020.101301
Shannon, S. & Opila-Lehman, J. (2016). Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. The Permanente Journal, 20(4), 108-111. doi:10.7812/tpp/16-005
Stasiulewicz, A., Znajdek, K., Grudzień, M., Pawiński, T., & Sulkowska, J.I. (2020). A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences, 21(8), 2778. doi:10.3390/ijms21082778
Stephens, M.A.C. & Wand, G. (2012). Stress and the HPA Axis: Role of Glucocorticoids in Alcohol Dependence. Alcohol Research, 34(4), 468-483.
Tanaka, M., Sackett, S., & Zhang, Y. (2020). Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology. Frontiers in Neurology, 11, 87. doi:10.3389/fneur.2020.00087
Tay, T.L., Béchade, C., D’Andrea, I., St-Pierre, M.K., Henry, M.S., Roumier, A., & Tremblay, M.E. (2017). Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan. Frontiers in Molecular Neuroscience, 10, 421. doi:10.3389/fnmol.2017.00421
Theodore, W.H., Wiggs, E.A., Martinez, A.R., Dustin, I.H., Khan, O.I., Appel, S., Reeves-Tyer, P., & Sato, S. (2012). Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia, 53(1), 129-133. doi:10.1111/j.1528-1167.2011.03309.x
Theodore, W.H., Hasler, G., Giovacchini, G., Kelley, K., Reeves-Tyer, P., Herscovitch, P., & Drevets, W. (2007). Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia, 48(8), 1526-1530. doi:10.1111/j.1528-1167.2007.01089.x
Turcotte, C., Blanchet, M.R., Laviolette, M., & Flamand, N. (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences, 73(23), 4449-4470. doi:10.1007/s00018-016-2300-4
Turna, J., Patterson, B., & Van Ameringen, M. (2017). Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depression and Anxiety, 34(11), 1006-1017. doi:10.1002/da.22664
Volkow, N.D., Swanson, J.M., Evins, L.E., DeLisi, L.E., Meier, M.H., Gonzalez, R., Bloomfield, M.A.P., Curran, H.V., & Baller, R. (2016). Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry, 73(3), 292-297. doi:10.1001/jamapsychiatry.2015.3278
Vučković, S., Srebro, D., Vujović, K.S., Vučetić, Č., & Prostran, M. (2018). Cannabinoids and Pain: New Insights from Old Molecules. Frontiers in Pharmacology, 9, 1259. doi:10.3389/fphar.2018.01259
Weis, W.I. & Kobilka, B.K. (2018). The Molecular Basis of G Protein–Coupled Receptor Activation. Annual Review of Biochemistry, 87, 897-919. doi:10.1146/annurev-biochem-060614-033910
Wheatley, M., Wooten, D., Conner, M.T., Simms, J., Kendrick, R., Logan, R.T., Poyner, D.R., & Barwell, J. (2012). Lifting the lid on GPCRs: the role of extracellular loops. British Journal of Pharmacology, 165(6), 1688-1703. doi:10.1111/j.1476-5381.2011.01629.x
Whiteford, H.A., Ferrari, A.J., Degenhardt, L., Feigin, V., & Vos, T. (2015). The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. PLoS One, 10(2), e0116820. doi:10.1371/journal.pone.0116820
Zou, S. & Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3), 833. doi:10.3390/ijms19030833


Ambika Nand Jha (Primary Contact)
Dhaval M Patel
Jha AN, Patel DM. Role of Cannabinoid Receptors in Psychological Disorder. Borneo J Pharm [Internet]. 2020Nov.30 [cited 2024May28];3(4):199-208. Available from:

Article Details